145 related articles for article (PubMed ID: 22828875)
1. p12(CDK2-AP1) inhibits breast cancer cell proliferation and in vivo tumor growth.
Zhou W; Guan X; Wang L; Liao Y; Huang J
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2085-93. PubMed ID: 22828875
[TBL] [Abstract][Full Text] [Related]
2. [Effect of CDK2-AP1 gene over-expression on proliferation and cell cycle regulation of breast cancer cell line MCF-7].
Guan X; Zhou W; Huang J; Wang L; Liao Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):990-6. PubMed ID: 23117465
[TBL] [Abstract][Full Text] [Related]
3. CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro.
He X; Xiang H; Zong X; Yan X; Yu Y; Liu G; Zou D; Yang H
Cancer Cell Int; 2014; 14(1):130. PubMed ID: 25550687
[TBL] [Abstract][Full Text] [Related]
4. Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
Peng H; Shintani S; Kim Y; Wong DT
Neoplasia; 2006 Dec; 8(12):1028-36. PubMed ID: 17217620
[TBL] [Abstract][Full Text] [Related]
5. p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin.
Kim Y; McBride J; Zhang R; Zhou X; Wong DT
Oncogene; 2005 Jan; 24(3):407-18. PubMed ID: 15543230
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1).
Greeve MA; Allan RK; Harvey JM; Bentel JM
J Mol Endocrinol; 2004 Jun; 32(3):793-810. PubMed ID: 15171713
[TBL] [Abstract][Full Text] [Related]
7. Evidence that P12, a specific variant of P16(INK4A), plays a suppressive role in human pancreatic carcinogenesis.
Poi MJ; Knobloch TJ; Yuan C; Tsai MD; Weghorst CM; Li J
Biochem Biophys Res Commun; 2013 Jun; 436(2):217-22. PubMed ID: 23727582
[TBL] [Abstract][Full Text] [Related]
8. ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.
Han W; Cao F; Gao XJ; Wang HB; Chen F; Cai SJ; Zhang C; Hu YW; Ma J; Gu X; Ding HZ
Int J Oncol; 2018 Sep; 53(3):937-948. PubMed ID: 29956756
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.
Zeng Z; Lin H; Zhao X; Liu G; Wang X; Xu R; Chen K; Li J; Song L
Clin Cancer Res; 2012 Aug; 18(15):4059-69. PubMed ID: 22675169
[TBL] [Abstract][Full Text] [Related]
10. Modulation of CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer.
Yuan Z; Gaba AG; Kent TS; Bennett A; Miller A; Weber TK
Oncogene; 2005 May; 24(22):3657-68. PubMed ID: 15806176
[TBL] [Abstract][Full Text] [Related]
11. p12CDK2-AP1 interacts with CD82 to regulate the proliferation and survival of human oral squamous cell carcinoma cells.
Chai J; Ju J; Zhang SW; Shen ZY; Liang L; Yang XM; Ma C; Ni QW; Sun MY
Oncol Rep; 2016 Aug; 36(2):737-44. PubMed ID: 27349208
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of anticancer activities of Poria cocos ethanol extract in breast cancer: In vivo and in vitro, identification and mechanism.
Jiang Y; Fan L
J Ethnopharmacol; 2020 Jul; 257():112851. PubMed ID: 32283190
[TBL] [Abstract][Full Text] [Related]
13. Roquin1 inhibits the proliferation of breast cancer cells by inducing G1/S cell cycle arrest via selectively destabilizing the mRNAs of cell cycle-promoting genes.
Lu W; Zhou M; Wang B; Liu X; Li B
J Exp Clin Cancer Res; 2020 Nov; 39(1):255. PubMed ID: 33228782
[TBL] [Abstract][Full Text] [Related]
14. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
15. Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells.
Mandriota SJ; Buser R; Lesne L; Stouder C; Favaudon V; Maechler P; Béna F; Clément V; Rüegg C; Montesano R; Sappino AP
J Biol Chem; 2010 Apr; 285(17):13092-106. PubMed ID: 20177072
[TBL] [Abstract][Full Text] [Related]
16. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1).
Martín A; Odajima J; Hunt SL; Dubus P; Ortega S; Malumbres M; Barbacid M
Cancer Cell; 2005 Jun; 7(6):591-8. PubMed ID: 15950907
[TBL] [Abstract][Full Text] [Related]
17. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
[TBL] [Abstract][Full Text] [Related]
18. p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer.
Figueiredo ML; Kim Y; St John MA; Wong DT
Clin Cancer Res; 2005 May; 11(10):3939-48. PubMed ID: 15897596
[TBL] [Abstract][Full Text] [Related]
19. Role of p12(CDK2-AP1) in transforming growth factor-beta1-mediated growth suppression.
Hu MG; Hu GF; Kim Y; Tsuji T; McBride J; Hinds P; Wong DT
Cancer Res; 2004 Jan; 64(2):490-9. PubMed ID: 14744761
[TBL] [Abstract][Full Text] [Related]
20. Mutation of Cys105 inhibits dimerization of p12CDK2-AP1 and its growth suppressor effect.
Kim Y; Ohyama H; Patel V; Figueiredo M; Wong DT
J Biol Chem; 2005 Jun; 280(24):23273-9. PubMed ID: 15840587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
